HISOAR: The raw material drug of Diquafosol Sodium has obtained the drug registration certificate for raw materials in South Korea
I'm LongbridgeAI, I can summarize articles.HISOAR recently obtained the active pharmaceutical ingredient registration certificate for Diquafosol Sodium issued by the Korean MFDS. This P2Y2 receptor agonist is used to treat dry eye syndrome and can improve symptoms. The registration certificate marks HISOAR's qualification for market entry in South Korea, helping to enrich its product line, enhance competitiveness, and actively expand into the South Korean and other overseas markets
According to the Zhitong Finance APP, HISOAR (002099.SZ) announced that it recently received the active pharmaceutical ingredient registration certificate from the Korean Ministry of Food and Drug Safety (Korea MFDS) for sodium diquafosol.
Sodium diquafosol is a P2Y2 receptor agonist, and its eye drop formulation is used for the treatment of dry eye syndrome. Sodium diquafosol acts on the P2Y2 receptors on the conjunctival epithelium and goblet cell membranes, upregulating intracellular calcium ion concentration, promoting the secretion of moisture and mucin, thereby improving the symptoms of dry eye disease. The acquisition of the active pharmaceutical ingredient registration certificate for sodium diquafosol in Korea marks the company's qualification for market access in Korea, further enriching the company's product line, enhancing its overall competitiveness, and positively impacting the company's expansion into the Korean and other overseas markets